PT - JOURNAL ARTICLE AU - Borges, Julian Yin Vieira TI - The Role of Coenzyme Q10 in Cardiovascular Disease Treatment: An Updated 2024 Systematic Review and Meta-Analysis of Prospective Cohort Studies (2000-2023) AID - 10.1101/2024.07.03.24309736 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.03.24309736 4099 - http://medrxiv.org/content/early/2024/07/04/2024.07.03.24309736.short 4100 - http://medrxiv.org/content/early/2024/07/04/2024.07.03.24309736.full AB - Background Cardiovascular diseases (CVDs) are the leading cause of death globally. Mitochondrial dysfunction is implicated in the pathogenesis of various CVDs. Coenzyme Q10 (CoQ10), a crucial component of the mitochondrial electron transport chain, has potential cardioprotective effects. This study aims to evaluate the efficacy of adding CoQ10 nutrient supplementation in the Treatment of Cardiovascular Disease Protocols in patients with CVDs.Methods This systematic review and meta-analysis assessed data from PubMed, Scopus, and Cochrane Library databases up to January 2024. Prespecified inclusion criteria were randomized controlled trials (RCTs) involving adult patients with CVDs, comparing CoQ10 supplementation with placebo or standard care. Exclusion criteria included non-randomized studies, studies without a control group, and those not reporting relevant outcomes. Data extraction and quality assessment were performed independently by two reviewers. The primary outcome was improvement in mitochondrial function, assessed through ATP production and mitochondrial respiratory capacity. Secondary outcomes included changes in systolic function, measured by ejection fraction. Statistical analysis was conducted using Review Manager software.Findings The search identified 243 studies, of which 5 RCTs met the inclusion criteria, encompassing a total of 1,200 participants (600 male, 600 female). CoQ10 supplementation significantly improved mitochondrial function in cardiomyocytes, evidenced by increased ATP production and enhanced mitochondrial respiratory capacity. Additionally, CoQ10 was associated with a significant improvement in systolic function, measured by ejection fraction (mean difference: 5.6%, 95% CI: 3.2% to 8.0%, p<0.001). The risk of bias across studies was generally low, with an I2 statistic of 25% indicating low heterogeneity.Interpretation This meta-analysis supports the beneficial effects of CoQ10 on mitochondrial function and systolic performance in patients with CVD. These findings suggest that CoQ10 supplementation could be a valuable adjunctive therapy in this population. However, further large-scale RCTs are necessary to confirm these results and determine the optimal dosage and duration of therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors